Lactate Clearance Goal-directed Therapy in Sepsis
Launched by NANFANG HOSPITAL, SOUTHERN MEDICAL UNIVERSITY · Aug 21, 2017
Trial Information
Current as of May 09, 2025
Unknown status
Keywords
ClinConnect Summary
Sepsis remains a great challenge for clinicians, early goal-directed therapy(EGDT), referring to a number of target-achieving indicators including systemic central venous oxygen saturation(ScvO2) after initial fluid resuscitation within 6 hours, has been one of the main treatment for sepsis. ScvO2 is the only indicator that reflects tissue oxygen metabolism. However, there're studies confirmed that ScvO2 oriented EGDT cannot reduce the mortality of sepsis. So it is important to find out a more effective indicator. Lactic acid is a product of anaerobic metabolism of the body, lactate clearan...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Older than 17 years old.
- • Primary diagnosis is sepsis, means being confirmed or suspected infection while have at least 2 points of quickSOFA(qSOFA).
- • Be transferred to intensive care unit (ICU) for the first time during this hospitalization.
- • Elevated lactate ≥3.0mmol/L.
- Exclusion Criteria:
- • Acute hemorrhage uncontrolled.
- • Pregnancy.
- • Known liver disease - Child-Pugh classes C, acute hepatic failure, severe hepatopathy accompany with prominent portal hypertension.
- * Known being in an immunosuppressive state:
- • 1. Suffering from any disease that is unrelated with sepsis that severely inhibits the immune to infection, such as: active hematological or lymphoma malignancy, or during immunosuppressive therapy, such as chemotherapy or radiotherapy.
- • 2. Known human immunodeficiency virus (HIV) serology positive.
- • Known chronic kidney disease.
- • Suffering from any disease that affects lactate kinetics, such as mitochondrial encephalopathy, congenital hyperlipidemia, Wernicke encephalopathy, etc. Or other probable cause of hyperlactatemia.
- • Took any drugs that affect lactate kinetics within the effective time window, such as taking metformin or phenylephrine within 1 week.
- • Suffering from any disease that restricts resuscitation, such as heart failure, cardiac surgery, severe heart disease etc, or suffered from a cardio-pulmonary resuscitation,.
About Nanfang Hospital, Southern Medical University
Nanfang Hospital, affiliated with Southern Medical University, is a leading medical institution in China renowned for its comprehensive clinical services and commitment to advancing healthcare through research and education. As a clinical trial sponsor, Nanfang Hospital leverages its state-of-the-art facilities and a multidisciplinary team of expert researchers to conduct innovative studies aimed at improving patient outcomes and contributing to the global medical community. The hospital's focus on ethical standards and patient safety ensures that all trials are conducted with the highest level of integrity and scientific rigor.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, Guangdong, China
Patients applied
Trial Officials
Chen Zhongqing, Ph.D
Study Chair
Southern Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials